Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott

This article was originally published in The Gray Sheet

Executive Summary

Introducing in the U.S. the Alcyon 300 and 300i bench-top clinical chemistry analyzers for routine and special chemistry testing at labs running fewer than 1,000 tests per day or 100,000 tests annually. Both analyzers received 510(k) clearance in February and offer a "49-assay menu of liquid reagents, an automated cuvette handler, 39 sample holders, 24 reagent positions and the ability to process up to 300 photometric tests per hour," the firm says. The initial menu of assays is expected to increase to 60 "within a year," while another 30 assays are under development, Abbott notes. The 300i offers an integrated ISE (chloride, potassium, sodium) module. The systems are based on technology developed by French manufacturer Alcyon Analyzer, which Abbott acquired in 1997 ("The Gray Sheet" Feb. 10, In Brief)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel